Prucalopride (** Motegrity (US), Resolor (Europe), Generic prucalopride **)

Other Medications

EU EMA Approved ES Funded by SNS other indication 1 Clinical Trials

Description

Prucalopride is not used in the treatment of colorectal cancer. It is indicated for chronic constipation and irritable bowel syndrome with constipation (IBS-C). Its mechanism does not target oncological processes, but rather enhances gastrointestinal motility.

Mechanism of Action

Prucalopride is a selective 5-HT4 receptor agonist that increases propulsive gastrointestinal motility by enhancing acetylcholine release from postganglionic cholinergic nerves in the myenteric plexus.

Side Effects

Nausea; Diarrhea; Abdominal pain; Headache

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05726097 Phase 3
Archived
Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
Sweden

Quick Info

Brand Name** Motegrity (US), Resolor (Europe), Generic prucalopride **
CategoryOther Medications
EU EMA StatusEMA Approved
ES Spain AccessFunded by SNS other indication
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
768 trials
Leucovorin
Other Medications
627 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.